DNA graphic

Joseph Craft, MD

Yale University


Characterization and Function of CD4 T Cell Subsets in Lupus

A plethora of new agents have been used therapeutically in lupus, including in nephritis, with mixed results. Possible explanations for these outcomes, apart from possible flaws in clinical trial design, are initiation of therapy after tissue inflammation and subsequent organ injury have occurred, and/or heterogeneity in immunopathogenesis; regardless, there is a pressing need to improve our understanding of disease mechanisms and organ injury in lupus, as a path toward selection of appropriate agents for therapeutic intervention. We will attempt to do this in our proposal, characterizing the cells that promote inflammation in lupus with the longer-term goal to identify new therapeutic targets in disease.


Learn and connect with our community!